Results: Overall progression-free survival (PFS), time to progression (TTP) and overall survival (OS) were 3.9, 4.1 and 9.1 months, respectively. For patients with CP class A versus B status, PFS was 4.3 versus 2.1 months, TTP was 4.2 versus 3.8 months and OS was 10.0 versus 3. 8 months. Extrahepatic spread was associated with worse outcomes but taken together with CP class, liver function played a greater role in reducing survival. Adverse events for the two CP groups were similar.
introduction Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and its incidence is rising in western countries [1] . In ∼50% of cases, HCC is diagnosed at an advanced stage when unsuitable for loco-regional treatment, with few systemic therapies available, and a median survival <1 year [1] [2] [3] [4] . The introduction of therapies targeting signalling pathways involved in cell proliferation and angiogenesis has improved the management of advanced HCC [5] .
Sorafenib, a small molecule multikinase inhibitor [6] , was the first systemic agent to prolong survival in patients with advanced HCC, as demonstrated in two phase III trials [4, 7] and it is now the reference standard for systemic treatment of these patients [3, 5, 8] . Both trials enrolled only patients with Child-Pugh (CP) class A liver function at baseline to limit the confounding effect of deaths due to advanced cirrhosis [4, 7] .
Two recent retrospective analyses and a case-control study evaluated sorafenib in patients with advanced HCC to assess differences in safety and efficacy based on CP status. They showed that the clinical outcome was poorer in CP class B patients, even if treatment maintained an acceptable safety profile [9] [10] [11] . A review of data from 267 patients with advanced HCC treated with sorafenib showed that CP class B patients had worse clinical outcomes. Although some patients with a score of 8-9 discontinued sorafenib due to cirrhosisrelated complications, this was still considered beneficial for CP class B patients [10] . Other investigations supported the feasibility of sorafenib in subjects with CP class B status, but were retrospective and/or conducted in a limited number of patients [11] [12] [13] . The recent results of an interim analysis of the GIDEON real-life study suggested that the safety profile of sorafenib is similar for CP class B and A patients. However, a shorter median overall survival (OS) was observed in CP class B patients, likely due to the poorer prognosis of liver cirrhosis [14] . A recent observational study of sorafenib in patients with intermediate (if ablative therapies failed in patients) or advanced HCC reported survival outcomes in line with those already published and, notwithstanding an increased rate of dose reduction/interruption in patients with more compromised liver function, CP class B patients still experienced survival benefits [15] . However, the conclusions of this study have been strongly questioned [16] .
The question whether or not to use sorafenib in CP class B patients is of major relevance as a large number of patients with advanced HCC present with suboptimal liver function. There is an urgent need to evaluate the safety of sorafenib in this population to identify which patients are eligible for treatment and at what dosage given the inconsistency of data from phase I and II trials on pharmacokinetics and recommended dose [9-11, 17, 18] . Additional studies are ongoing, the results of which are eagerly awaited.
We report the results of a descriptive analysis conducted in patients included in the first phase of a dual-phase clinical trial of sorafenib in advanced HCC (results of the second phase were described elsewhere [19] ). The aim of this study was to prospectively investigate the feasibility of sorafenib treatment in patients with poorer (CP class B) compared with better (CP class A) liver function.
patients and methods

patient selection
Patients were eligible for this multicentre, phase II, open-label trial if they had cyto-histologically confirmed advanced HCC unsuitable for resection or loco-regional therapy, Barcelona Clinic Liver Cancer (BCLC) stage B or C, CP liver function class A or B, Eastern Cooperative Oncology Group (ECOG) performance status (PS) score ≤2, adequate haematological, hepatic (according to CP status) and renal function and a life expectancy of ≥12 weeks. Patients must be untreated with targeted therapies and have at least one measurable target lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST) v.1.0.
All patients provided written informed consent before enrolment in the study. The study was approved by the institutional review board or ethics committee at each centre and complied with the provisions of the Good Clinical Practice guidelines, the Declaration of Helsinki and Italian national laws.
study design
The study consisted of two consecutive phases. During the first phase, all patients received continuous oral treatment with sorafenib 400 mg twice daily until radiological progression (as defined by RECIST), symptomatic progression or deterioration of PS, unacceptable toxic effects or patient withdrawal. Treatment interruptions and dose reductions were permitted for drug-related adverse events (AEs).
The second phase of the trial was initiated on radiological disease progression. Patients were randomized to sorafenib dose escalation (600 mg twice daily) or best supportive care. The randomization was conducted according to the study protocol and patients were allowed to decline inclusion in the second phase of the trial.
outcomes and assessments
We report here the results of a non pre-specified descriptive analysis of data from all patients included in the study.
The present analysis assessed progression-free survival (PFS), defined as time from enrolment to clinical or radiological disease progression or death. Tumour measurements were carried out at screening, every 8 weeks during treatment, and at the end of treatment by computed tomography (CT) or magnetic resonance imaging. Time to last observation was used if a patient had not progressed or was lost to follow-up and PFS was censored. Additionally, this analysis included an evaluation of the OS, defined as time from enrolment to death from any cause. Time to last observation was used if, by study end, the patient was still alive, and OS was censored. Time to progression (TTP) was calculated from enrolment until radiological progression or until last CT evaluation for progressionfree patients, censoring patients who died. Safety was assessed in all patients receiving at least one dose of sorafenib.
We reviewed patients every 4 weeks and at the end of treatment to assess compliance, based on tablets accountability, and safety, based on AEs, clinical laboratory tests, physical examination and measurement of vital signs.
statistical analysis
All data were analysed by descriptive statistics. Demographic and clinical characteristics were compared by the χ 2 test (Yates' corrected) or Fisher's exact test, as appropriate. The Wilcoxon-Mann-Whitney test was used to investigate differences among medians. Survival curves for PFS and OS were computed by means of the Kaplan-Meier analyses. Patients were stratified according to gender, age (median age <68 or ≥68 years), tumour histotype, extrahepatic spread and CP status. Differences among subgroups were evaluated by the log-rank test. Statistically significant variables in the univariate analysis were tested using multivariate Cox proportional hazards regression models and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. A P-value of <0.05 was considered statistically significant. All statistical analyses were carried out using R-package v. 2.0.
results
Between April 2007 and July 2008, 300 patients were enrolled in the study. Three patients never received sorafenib and data relevant to 297 patients are presented. The distribution of patients across centres (supplementary Table S1 , available at Annals of Oncology online) and a patient flow chart (supplementary Figure S1 , available at Annals of Oncology online) are available online. Baseline characteristics for all patients, and according to CP status, are summarized in The median PFS for the total patient population was 3.9 (0.1-35.3) months. CP class and age showed statistically significant differences and maintained their effect in multivariate analysis. PFS for patients with CP class A or B was 4.3 (0.1-35.3) and 2.1 (0.3-27.3) months, respectively (logrank, P < 0.001; Table 2 ). In the multivariate analysis, CP class B patients had a greater risk of disease progression or death (HR 1.87, 95% CI: 1.41-2.48, P < 0.001), corresponding to a 47% risk reduction in PFS in the CP class A compared with the class B subgroup (Figure 1 ). Patients <68 years compared with those ≥68 years presented a reduced risk in PFS (HR 0.77, 95% CI: 0.60-0.97, P = 0.026).
Data on TTP were available in 240 patients (80.8%; 206 CP class A and 34 CP class B), 57 patients did not present a radiological evaluation post-enrolment due to death (15.8%), AEs (36.8%) and other reasons (47.4%). Reasons for exclusion from this analysis are shown in the patients' flow chart (supplementary Figure S1 , available at Annals of Oncology online). The median TTP was 4.1 (0.03-16.0) months for the total patient population and was not statistically different according to CP status. TTP for CP class A patients was 4.2 (0.03-31.7) and for CP class B patients was 3.8 (range 1.3-16.0) months (log-rank, P < 0.102). The median OS was 9.1 (0.4-49.1) months for the total patient population ( Table 2) . As for PFS, CP class B patients had a statistically significant greater risk of death than those with CP class A status (HR 3.23, 95% CI: 2.38-4.39, P < 0.001). The median OS was 10.0 (0.5-49.1) for CP class A patients and 3.8 (0.4-27.3) months for CP class B patients (log-rank, P < 0.001) (Table 2, Figure 2) ; the risk reduction for CP class A patients compared with those with CP class B was 69%. In the overall patient population, there were also statistically significant differences in OS according to AST baseline values (log-rank, P = 0.008), vascular invasion (log-rank, P = 0.049) and HCC disease extent (log-rank, P = 0.025); the latter was confirmed in the multivariate evaluation (Table 2) . Patients with extrahepatic spread had a greater risk of death than those with intrahepatic disease (HR 1.55, 95% CI: 1.15-2.08, P = 0.026). Patients with CP class B had a higher risk of death than those with CP class A status, irrespective of the extent of disease (P < 0.001), emphasizing the prognostic role of CP classification over disease extent (Figure 3) . A subgroup analysis according to CP score B7 versus B8 + B9 showed a statistically significant difference in terms of OS (4.6 versus 2.9 months; P = 0.048), whereas non-statistically significant differences were observed in PFS and TTP. Due to the small number of CP class B patients, we did not perform further subgroup analyses.
Finally, a statistically significant correlation between drug exposure and outcome in terms of TTP and OS was observed in the overall patient population (P < 0.001), whereas no outcome differences were documented between high-and lowvolume centres.
safety
The type and the incidence of AEs were similar in the overall patient population and in patients with CP class A and B Table S2 , available at Annals of Oncology online). Most frequent AEs of any grade in the overall population were fatigue (55%), diarrhoea (54%), weight loss (51%), hand-foot skin reaction (HFSR; 37%) and stomatitis (36%), most of which were grades 1 and 2 (according to Common Terminology Criteria for Adverse Events, v 3.0), but with fatigue, diarrhoea and HFSR occurring as grade 3 and 4 events in 15%, 14% and 10% of patients, respectively. The most frequent AEs in CP class A patients were fatigue (58%), diarrhoea (58%), weight loss (53%), HFSR (44%) and abdominal pain (32%), mostly of grade 1 and 2 severity, with fatigue, diarrhoea and HFSR of grades 3 and 4 in 16%, 15% and 12% of patients, respectively. In CP class B patients, fatigue, stomatitis, diarrhoea and weight loss had the highest incidence (44%, 41%, 38% and 38%, respectively), mostly of grades 1 and 2, but cachexia and liver failure (the inability of the liver to perform its normal function due to cirrhosis) occurred as grade 3 and 4 events in 9.5% and 4.8% of patients and diarrhoea and fatigue as grade 3 event in 13% and 11% of patients, respectively. Fourteen deaths (4.7%) occurred within 30 days from the last dose of the study drug, due to liver failure (eight), cachexia (four) and bleeding (two). Six deaths (2.6%) occurred in CP class A patients (three liver failure, two bleeding and one cachexia) and eight (12.7%) in CP class B patients (five liver failure and three cachexia; P = 0.090). Liver failure and cachexia were the most frequent causes of death and were attributed to liver disease progression and not to the study drug.
discussion
Sorafenib was the first systemic therapy to produce a survival benefit in patients with advanced HCC [4, 7, 20] . The SHARP trial in 602 patients demonstrated prolonged median OS (10.7 versus 7.9 months; P < 0.001) and prolonged time to radiological disease progression (5.5 versus 2.8 months; P < 0.001) for sorafenib compared with placebo [4] . Similar survival benefits emerged from the Asia-Pacific study, in which patients treated with sorafenib had a substantially longer median OS (6.4 versus 4.2 months) and median TTP (2.8 versus 1.4 months) over placebo [7] . It is well established that in patients with advanced HCC, CP class B status predicts for poorer outcomes [21] . As both the largescale registration sorafenib trials enrolled CP class A patients, the viability of sorafenib treatment in patients with advanced HCC and poorer liver function was largely unknown [4, 7] .
Two recently published retrospective analyses and a casecontrol study indicate that CP class B patients with advanced HCC treated with sorafenib had poorer clinical outcomes than CP class A patients [9] [10] [11] . However, sorafenib is considered beneficial for CP class B patients with less compromised liver function and the safety profile is similar in the two subgroups, supporting the viability of sorafenib treatment in this population [10] [11] [12] [13] [14] [15] . Nonetheless, the role of sorafenib in CP class B patients remains controversial.
To our knowledge, ours is the largest study prospectively evaluating the use of sorafenib in CP class B and A HCC patients. Data for our analysis were collected in a selected population of patients with advanced HCC who met stringent eligibility criteria for enrolment in a phase II trial. However, it must be noted that this analysis, albeit prospective was not prespecified and not specifically designed to compare outcomes in patients according to the CP class. Therefore, these findings should be regarded as descriptive only. In CP class A patients, the efficacy and safety results are in line with those observed in the SHARP and in the Asia-Pacific trials [4, 7] . In particular, tolerability data were similar to those reported in other sorafenib trials [4, 7, 14] . The most important finding of our study regards the use of sorafenib in CP class B patients. Indeed, our data do not indicate a worse safety profile nor the need to modify the sorafenib dose in patients with more compromised liver function and this is in line with what recently observed in other studies [10] [11] [12] [13] [14] . We reported a statistically significant difference in PFS depending on liver function status. Patients with CP class B status had worse overall outcomes and CP class A patients had a 47% risk reduction in PFS compared with those with CP class B. This is in line with published data [10] . The duration of sorafenib treatment was the only substantial difference between the two groups. A greater proportion of patients with better CP liver function was treated for >3 months (59% class A versus 27% with class B), and the proportions of patients treated for ≤3 months were 41% and 73%, respectively. However, outcome differences among CP subgroups could also be due to the poorer prognosis associated with more severe cirrhosis and not to cancer severity [10, 14, 22] . PFS also differed with the age of patients: younger patients (<68 years) had a longer median PFS, with a HR for progression of 0.77 compared with patients ≥68 years. While liver function and disease spread (intraversus extrahepatic disease), as observed in the multivariate analysis, independently influenced OS, survival appears to be affected by liver function more than by disease spread. CP class B patients, regardless of disease spread, had a higher risk of death than those with CP class A function and extrahepatic disease. Moreover, CP class B patients with a B8 + B9 score did worse in terms of OS compared with those with a B7 score. These results confirm that CP liver function status affects the clinical outcomes in patients with advanced HCC treated with sorafenib.
A further finding of our study was the statistically significant correlation between drug exposure and outcome in terms of TTP and OS (P < 0.001), emphasizing the importance of maintaining the highest dose intensity acceptable for each patient. Importantly, despite the multicentre nature of this study, no differences in terms of drug exposure or outcome were documented between highand low-volume centres.
In conclusion, although limited by the statistical design of our study, tolerability data suggest that CP class B patients might be safely treated with sorafenib. However, its activity in this patient population remains to be defined, bearing in mind that it is not a homogeneous group. Further prospective trials specifically designed to investigate the efficacy and safety of sorafenib in CP class B subgroups, 
